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Abstract It has been suggested that a more precise
selection of predictive biomarkers may prove useful in the
early diagnosis of type 2 diabetes (T2D), even when
glucose tolerance is normal. This is vital since many T2D
cases may be preventable by avoiding those factors that
trigger the disease process (primary prevention) or by use
of therapy that modulates the disease process before the
onset of clinical symptoms (secondary prevention) occurs.
The selection of predictive markers must be carefully
assessed and depends mainly on three important parame-
ters: sensitivity, specificity and positive predictive value.
Unfortunately, biomarkers with ideal specificity and sensi-
tivity are difficult to find. One potential solution is to use
the combinatorial power of different biomarkers, each of
which alone may not offer satisfactory specificity and
sensitivity. Recent technological advances in proteomics
and bioinformatics offer a great opportunity for the discov-
ery of different potential predictive markers. In this review,
we described a cellular T2D model as an example with the
intent of providing specific enrichment and new identifica-
tion strategies, which might have the potential to improve
predictive biomarker identification and to bring accuracy in
disease diagnosis and classification, as well as therapeutic
monitoring in the early phase of T2D.
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General introduction
Type 2 diabetes (T2D) is one of the fastest growing health
concerns worldwide with a prevalence of approximately 5%
in the United States (American Diabetes Association,
2002). Due to sedentary lifestyle, unhealthy nutrition and
a prolonged lifespan, the prevalence in the developed and
developing countries is still increasing. Health experts have
warned of a global epidemic of diabetes caused by a rise in
overweight and obesity. There are currently 120–140
million people worldwide with T2D, and if trends continue,
this number is predicted to double in the next 25 years. In
the Western world, around 90% of T2D cases are
attributable to weight gain. Because of the severe health
and cost implications of this disease, organizations such as
the International Diabetes Federation (IDF) have called for
increased efforts to prevent its development. The IDF
estimates that 314 million people worldwide, or 8.2% of the
global population, have impaired glucose tolerance (IGT), a
state that often precedes T2D. In addition, T2D is a heavily
under-diagnosed disease and is usually only discovered at a
late stage, when the first complications occur. Detection in
an early state would be highly desirable, as the progression
of T2D can then be slowed down by simple, nonpharmaco-
logic means, i.e. weight loss and exercise. The existing
diagnostic tests, fasting plasma glucose (FPG), the oral
glucose tolerance (OGT) test or the euglycemic hyper-
insulinemic clamp are either relatively insensitive and
inaccurate or so difficult to perform that they do not lend
themselves to mass screening.
The identification of a reliable, accurate, cost-effective
and non-invasive test for T2D that could be applied in the
prediabetic state would present a sizeable opportunity for
diagnostics and would be valuable as a monitoring marker
for clinical studies in T2D. Although significant progress
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has been made in the treatment of T2D, new insulin
sensitizing drugs such as the thiazolidinediones display
significant side-effects and major health concerns still
prevail for this class of compounds. Most importantly,
there is no medication on the market that slows down the
progressive beta-cell (β-cell) failure, a hallmark of late-
stage T2D. The identification of pathways and factors
involved in either insulin-resistance of skeletal muscle or β-
cell failure could lead to new drug targets and the
development of novel pharmaceuticals for the treatment of
impaired glucose tolerance (IGT) and for the prevention of
β-cell failure, respectively.
Beta-cell failure is explained by both a relative loss of β-
cell mass as well as secretory defects including enhanced
basal insulin secretion by the β-cells and a selective loss of
sensitivity to insulin mainly in skeletal muscle but also in
other organs. Beta-cell failure is the last step in the
progression of type 2 diabetics towards dependence on
external insulin. The loss of β-cell function is believed to
be triggered by long-term exposure to enhanced levels of
glucose and lipids (glycol- and lipotoxicity). However, the
molecular mechanisms of this phenomenon are poorly
understood. Although insulin sensitizers hold some prom-
ise, there is currently no proven treatment for T2D patients
that would prevent progression towards β-cell failure. It
would also be useful to identify better targets and/or
predictive markers for β-cell failure or function that are
more sensitive or more reliable than the targets/markers
commonly used, such as proinsulin or its processing
products insulin or C-peptide. This is vital since many
T2D cases may be preventable by avoiding those factors
that trigger the disease process (primary prevention) or by
use of therapy that modulates the disease process before the
onset of clinical symptoms (secondary prevention) occurs.
For a better understanding of the molecular events leading
to the loss of β-cell function and to define possible targets
for a function-preserving treatment a cellular model for β-
cell failure is thus required. Furthermore, there is currently
no good test available to assess β-cell functionality. Such a
test would be of great value in potential clinical trials for
pharmaceuticals that preserve β-cell function. For this
reason, several labs systematically analyzed β-cell failure
to identify significant changes that occur after exposure to
both palmitate and high glucose [1].
The rat insulinoma cell line INS-1 displays β-cell-like
features making it a good in vitro model for this cell type. It
has preserved many β-cell characteristics, including
glucose-stimulated insulin secretion. Furthermore, study of
these β-cells with decreased insulin secretion as compared
to cells with normal function could lead to a better under-
standing of the biology of β-cell failure and could highlight
possible targets for therapeutic intervention. Study of these
cells may also lead to the identification of markers for β-
cell failure or function that are more reliable or sensitive
than the C-peptide.
In conclusion, important steps were made towards the
identification of β-cell specific proteins that might serve in
the future as predictive markers for β-cell function or
failure. Furthermore, it would be an advantage to identify
such markers that can be detected in plasma of humans.
Follow-up experiments using animal models and human
blood and plasma samples were designed to validate
opportunities to pharmaceutically target β-cell failure and
to generate novel medicines for T2D.
Current status of diabetes diagnostics
Blood glucose testing is the most commonly used method
for the diagnosis and monitoring of diabetes mellitus. FPG
levels and plasma glucose levels 2 h after the uptake of a
75 g dose of glucose are two possible methods to detect the
disease. Two independently obtained positive test results are
required to establish the diagnosis. As it is easier and less
time-consuming to perform, the FPG test is recommended
by the American Diabetes Association. However, FPG levels
will only be increased, when an increased insulin secretion
fails to compensate for insulin resistance, which will only be
the case in late stages of T2D. The OGT test and the
euglycemic hyperinsulinemic clamp [1] are two methodolo-
gies that have the potential to detect insulin resistance at an
earlier stage, but are relatively time-consuming to perform
and are not amenable to mass testing. Once the diagnosis is
established, the efficacy of a treatment regimen can be
monitored by measuring glycated hemoglobin (HbA1c)
which reflects the plasma glucose levels over the last 4–
6 weeks [2]. For an assessment of β-cell function, the
measurement of the concentration of C-peptide is, at this
time, the best method available [3, 4]. Measurement of this
parameter is however not recommended for clinical practice
as it suffers from a large variability [5].
Current biomarkers for diabetes
The classical risk factors for type 1 diabetes (T1D) are,
apart from familiar predisposition, genetic markers, like
certain HLA-DQ or CTLA4 genotypes associate with
increased risk of developing T1D. The detection of auto
antibodies to islet cell antigens (ICA), insulin, glutamic acid
decarboxylase (GAD-65), or IA-2 protein tyrosine phos-
phatase marks the onset of the autoimmune disease and can
be detected years before clinical symptoms of diabetes
appear. While certain variants in genes encoding a β-cell
specific ion-channel (SUR8/Kir6.2) are associated with
transient or permanent neonatal diabetes and mutations in
the ABCA1 gene have recently been associated with T2D
(reviewed in [6]), obesity is still the greatest known risk
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factor for T2D. Though familiar clustering of T2D implies
the existence of genetic risk factors, these are still
unknown.
While for T1D early diagnostic markers exist in the form
of auto antibodies, T2D can so far only be diagnosed when
the clinical symptoms appear at the later stages of the
disease. Metabolic markers like hyperglycemia, insulin or
C-peptide level, and HbA1c are used to diagnose diabetes
and monitor the disease state in all types of diabetes. Since
an early diagnosis and an early therapy hold the greatest
promises to postpone full disease development and to delay
secondary morbidities like cardiovascular diseases, reliable,
sensitive markers for early T2D are a key concern.
Several novel biomarkers for T2D have been reported
and reviewed recently [7]. Among the T2D marker
candidates are markers of fatty liver routinely tested like
alanine aminotransferase (ALT) and γ-glutamyl transferase
(γ-GT), both well correlated with diabetes risk [8]. Low
levels of sex homone binding globuline (SHBG), a hepati-
cally secreted hormone negatively regulated by insulin, can
indicate high insulin levels, insulin resistance and risk of
T2D, a correlation that is stronger in women than in men
[9]. Low SHBG has been reported to be predictive of
gestational diabetes [10]. Inflammatory markers interleukin
6 (IL-6) and C-reactive protein (CRP) induced by IL-6 have
also been associated with T2D [11], as has another acute
phase marker ferritin [12]. Some studies suggested that
CRP and IL-6 levels positively correlated with insulin
resistance and with the risk of acquiring type 2 DM.
However there is no correlation between plasma ferritin
level and glycemic control or diabetic microangiopathic
complications. Serum ferritin, initially a marker of cellular
iron stores, is therefore not fully validated as a indicator of
T2D risk [13]. Adiponectin, a hormone produced by
adipocytes and involved in the regulation of fat and glucose
metabolism, has an inverse correlation to diabetes, i.e. low
adiponectin levels correlate with high T2D risk [14] and
genetic variants of adiponectin have been associated with
increased risk of T2D [15]. Adiponectin exerts insulin-
sensitizing and anti-infamatory functions through two
different seven-transmembrane receptors expressed pre-
dominantly in β-cells and skeletal muscles (ADIPOR1) or
the liver (ADIPOR2) [16]. Leptin, another adipocyte
hormone regulates appetite and has been associated with
T2D but the significance is unclear, as leptin levels can be
deregulated in leptin resistant obese patients and a positive
and a negative association with T2D can be found [17].
Tissue plasminogen activator (tPA) and its inhibitor PAI-1
have also been linked to T2D [18–20]. Both of these
proteins can be secreted form endothelial cells and high
plasma levels usually reflect endothelial stress or inflam-
mation. PAI-1 can also be released from adipocytes and
hepatocytes and its plasma levels increase with adiposity,
weakening the association with T2D. Like tPA and PAI-1
von Willebrand factor (vWF) is a maker of endothelial
dysfunction associated with risk of T2D in the literature
[21] and like the former it is induced by proinflammatory
cytokines. The association of vWF with T2D is less robust
and significance is lost after adjustment for obesity or
inflammatory cytokines in some studies [20]. Other risk
factors for T2D have been described, many of these are also
associated with obesity or inflammation and thus might not
be useful to discern an obese patient at risk to develop T2D
form one not at risk. Furthermore, many risk factors have
been analyzed only in small study groups. All risk factors
identified so far are present in healthy populations as well
though at a different levels. But it is not only T2D that will
influence their expression level, age, sex, ethnicity might
also play a role increasing the variability and reducing the
specificity.
Current treatment scheme for T2D
In the early stages of the disease, weight loss and an
increase in physical activity are often sufficient to restore
insulin sensitivity (American Diabetes Association, 2002).
If this regimen fails, non-insulinotropic agents such as
acarbose or metformin (and glitazones) are the first-line
therapeutics. When insulin levels drop, insulin secreta-
gogues (sulfonylureas, repaglinide) need to be added to the
therapeutic regimen. Eventually, when this regimen has
become insufficient, insulin injection becomes necessary.
Scientific rationale for β-cell failure as a disease model
for T2D
Beta-cell failure occurs at a late stage in the progression of
T2D and leads to overt diabetes. The mechanisms by which
β-cell function is impaired are largely unknown but have
been shown to involve hyperglycemia as well as hyperlip-
idemia [22].
Interestingly, β-cell failure does not appear to be an
inevitable consequence of hyperinsulinemia. Some animal
models of hyperinsulinemia/diabetes show persistent life-
long hyperinsulinemia (e.g. ob/ob mice, fa/fa rats) while
others show deteriorating β-cell function and apoptosis of
β-cells (e.g. db/db mice, Psammomys obesus, and rhesus
monkeys) [23]. The reasons for these differences are
unclear and include genetic factors [24]. The situation in
humans may be similar, as insulin resistance is an almost
inevitable consequence of obesity but only some individ-
uals have frank diabetes and progress into insulin depen-
dence. The fact that β-cell failure is avoidable in some
animal models encourages research towards the prevention of
β-cell failure. In vitro studies have demonstrated a glucotoxic
effect that was only partially reversible [23, 25, 26].
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Lipotoxicity plays an equally important role [27, 28]. A
profound effect on β-cell function is observed in models
combining both factors [22]. Some scientists speculate
that these two mechanisms are independent of each other
and involve distinct pathways (Dr. M. Donath, Zurich,
personal communication). Apoptosis plays a critical role
in β-cell failure and T2D [29] and is induced by Fas-FasL
interaction where the latter is constitutively expressed by
β-cells and the former induced by cytokines and glucose
(Dr. M. Donath, personal communication). FLIP blocks
the cascade from Fas-FasL interaction➔ caspase 8➔ 3 and
finally apoptosis and even reverses the effect of high
glucose, thus resulting in proliferation instead of apopto-
sis. This suggests that prevention of β-cell failure is
feasible. The apoptotic effect of lipids, mediated by Bcl-2
and ceramide, is less well documented. Importantly,
although apoptotic pathways have been explored exten-
sively, the present review addresses functional β-cell
failure outside apoptosis. A decrease in β-cell mass was
observed in patients with advanced T2D but not in the
early stages of the disease [30]. The metabolic disturban-
ces of most patients will go unnoticed until frank
hyperglycemia is detected. However, the vast majority of
patients will remain in a stage of partial compensation
before moving on to dependence on exogenous insulin. At
this particular stage, compounds preventing β-cell failure
could be applied, therefore the goals of our proteomics
study are twofold: (i) The first line of experiments will be
directed towards the identification and validation of a
potential monitoring marker for clinical studies. Indeed,
the current gold standard for the measurement of β-cell
function, the measurement of the insulin C-peptide, is not
sufficiently reliable for this purpose. To ensure its broad
acceptance, a marker would have to be established well in
advance of a clinical program aimed at demonstrating
disease modifying (i.e., β-cell failure preventing) efficacy
of a novel compound. (ii) Secondly, the changes in protein
expression patterns should be studied in order to improve
our understanding of the biological processes involved in
β-cell failure, ultimately leading to the identification of
pathways and novel targets for therapeutic intervention.
Methodology
Cellular model system for the identification of potential
markers of β-cell failure
Isolated islets and insulin secreting cell lines become
desensitized upon exposure to high levels of glucose and
palmitate [22]. The rat insulinoma cell line INS-1 and the
mouse cell line Min6 appear to be the best available model
cell lines at this time [31, 32]. They have retained many
characteristics of primary β-cells, including the suscepti-
bility to the combined toxic effect of glucose and lipids.
Two classes of proteins could fulfill the criteria for a
marker of β-cell failure: (i) Highly expressed β-cell
specific proteins could become detectable in the blood-
stream upon cell death, and (ii) the level of β-cell specific
secreted proteins could significantly drop as a sign of
impaired β-cell function. Ideally the latter would be
constitutively secreted and not depend on glucose concen-
tration as shown in the results of the OGTT. For this
purpose, a catalogue of proteins expressed in β-cell lines
was established to identify β-cell specific proteins that have
the potential to become detectable in human blood and that
could serve as a marker for β-cell failure. Beta-cell specific
proteins identified by this strategy will have to be first
validated in an animal model for β-cell failure, for example
in blood samples collected from rat strains rapidly
developing full-blown diabetes (e.g. ZDF rats), before
human blood samples can be tested.
New enrichment and identification strategies
of differentially regulated proteins in failing β-cells
Beta-cell failure can be mimicked in several cell culture
models by adding a combination of fatty acids and
increased concentrations of glucose to the culture medium
as shown in [22, 28]. Comparison of expression patterns
from untreated cells, cells treated with either a fatty acid or
high glucose, and cells treated with both fatty acid and high
glucose should highlight gene products whose regulation
correlates with β-cell failure in a cell culture model. The
results from this study directed the proteome comparison
towards the compartments that appeared most affected
based on the transcript analysis. In a second step these
changes can be validated using animal models such as ZDF
rats or db/db mice. Finally, findings from the primary β-
cells must be further validated by using human plasma
samples from different donor groups (e.g. patients with
impaired glucose tolerance (IGT), impaired fasting glucose
(IFG), type 2 diabetes (T2D), type 1 diabetes (T1D), and
healthy donors).
Critical points of the β-cell failure model:
– A reliable, reproducible model of β-cell failure induced
by gluco- and lipotoxicity after a reasonable exposure
time must be established first.
– Triggering failure of the cultured cells to secrete insulin
is a time-dependent process that must be carefully
monitored (see Fig. 2). Establishing the appropriate
monitoring readouts is therefore crucial to this project.
Selecting the appropriate time point based on the
measurement of the selected parameters is difficult
and requires kinetic measurements.
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– Up-scaling of the cell culture is necessary for obtaining
sufficient quantities of starting material for a proteome
analysis (see Fig. 4). This may lead to variations.
Careful monitoring by measurement of the parameters
defined by the pilot experiments is therefore mandatory.
– Beta-cell specific proteins, even if highly abundant
intracellularly, or secreted proteins may not be present
in blood in detectable quantities. Therefore highly
sensitive ELISA must be used to validate findings in
human blood samples
– A fractionation scheme that efficiently enriches for
secretory vesicles has to be established.
– The concentration of secreted proteins in the culture
supernatant is likely to be very low. The accessibility of
these proteins by mass spectrometric methods should
be therefore assessed.
Methodology approach and cellular study design
Features ofβ-cell failure can be performed by chronic exposure
of β-cells to a combination of high glucose/fatty acids (FAs),
suggesting that hyperlipidemia as well as hyperglycemia may
contribute to decompensation of β-cells. INS-1 cells pretreated
for 30 h with a combination of 10 mM glucose and 0.5 mM
palmitate can be used for these experiments. Establishment of
β-cell culture conditions for proteomics analysis should be
carried out in parallel (see Figs. 1 and 3). Screen INS-1 cell
cultures under treatment with glucose/fatty acids and identi-
fication of different expressed protein levels between glyco/
lipotoxicity and combination. Focus on secreted proteins in
the supernatant as possible markers for β-cell failure/function.
Enrichment and identification of secreted INS-1 peptides/
proteins in the medium by heparin chromatography followed
by LC-MS were applied.
General introduction and strategies for enrichment
and purification of secreted proteins
In order to identify proteins secreted by INS-1 [31, 33] two
methods can be applied: (i) Fractionation of the cells by
differential sedimentation into subcellular compartments with
subsequent identification of the proteins based on their peptide
mass fingerprint using MALDI-TOF mass spectrometry, and
(ii) enrichment of glycoproteins by heparin chromatography
followed by one-dimensional SDS-PAGE and identification
of proteins by analysis of the tryptic peptides resulting from
protein digest by liquid chromatography coupled to tandem
mass spectrometry resulting in identification based on protein
sequence tags (see Fig. 4). The combination of these two
purification strategies allowed us to increase the efficiency of
protein identification in the cellular compartments as well as
in the medium of cultured cells.
Enrichment of putative secreted proteins by heparin
columns from the medium and identification by LC-MS
Visualization and identification of secreted proteins may
facilitate the identification of novel drug targets and different
biomarkers including predictive markers. However, not all


























































































































Fig. 2 Characterization and whole protein profiling of INS-1 cells: Model of β-cell failure induced by gluco- and lipotoxicity after 35 h exposure time
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detection by two-dimensional or one dimensional polyacryl-
amide gel electrophoresis. In order to visualize and identify
low-copy gene products with signaling function, enrichment of
low-abundance cytosolic proteins by applying heparin chro-
matography were chosen because heparin has a high protein
binding capacity and can discriminate and enrich proteins with
minor differences in their pI-values and glycosylation patterns
[34, 35]. As most secreted proteins are glycosylated, [36]
heparin sepharose and/or lectin columns are versatile tools for
the enrichment of many classes of glycosylated proteins such
as proteins with signaling functions, growth factors, coagula-
tion factors and steroid receptors [37, 38]. The ligand in a
heparin sepharose column is a naturally occurring sulfated
glycosaminoglycan, which is extracted from the native
proteoglycan of porcine intestinal mucosa. Heparin consists
of alternating units of uronic acid and D-glucosamine, most of
which are substituted with one or two sulphate groups.
Immobilized heparin has two main modes of interaction with
proteins: It can operate as an affinity ligand; e.g., in its
interaction with coagulation factors and it can also function as
a high capacity cation exchanger because of its anionic
sulphate groups, leading thus to an additional enrichment of
positively charged proteins.
To enrich for secreted rat insulinoma proteins with
signaling function heparin chromatography was applied
prior to proteomic analysis. The column was operated with
a syringe instead of a liquid chromatography pump. Elution
was performed by increasing the ionic strength with 2 M
NaCl. Separation of the eluted proteins was carried out by
one-dimensional (1D-) polyacrylamide gel electrophoresis
(PAGE) and the proteins were identified by multidimen-
sional protein identification technology (MudPIT) tandem
mass spectrometry [39, 40] in combination with in silico
analysis (see Figs. 4 and 5).
Moreover, heparin chromatography may be useful in
the depletion of albumin from body fluids, such as
plasma and cerebrospinal fluid, in which it represents
more than 50% of total proteins [34, 41]. For example,
serum albumin, which is represented by a strong band in
the starting material (see Fig. 6), was completely recov-
ered in the flow-through fraction. Specific removal of
albumin, as well as of other high abundance proteins
allowed the visualization and identification of minor
components of the samples, whose levels may change in
certain disorders [42]. In addition to the easier design of
protein purification steps, use of selected chromatography
steps prior to the LC-MS/MS, can significantly facilitate
the analysis of complex protein mixtures. Methodological
sample preparation and purification, as well as systemat-
ically identification by MudPIT and MALDI are published
in detail [43, 44].
Identification of putative secreted proteins by in silico analysis
Secreted proteins are characterized by a signal peptide
sequence that helps in threading the protein’s N terminus
through a membrane before it is cleaved off by a signal
peptidase. Signal peptides are only loosely defined, often
with a positively charged polar section, followed by a
hydrophobic stretch, and a short pattern around the
cleavage site.
The web tool that are used in order to identified or
predicted signal peptide from SwissProt, was an developed
software tool based on a set of specialized, manually
curated Hidden Markov Models (HMMs) that attempt to
recognize the (sparse) sequence features common to signal
peptides or anchors, respectively [43]. As these sequence
signals cannot be reliably predicted, the “signal” and
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Fig. 3 Flowchart of proteomics approach to identify markers of β-cell
failure using mass spectrometry (MudPIT=Multi protein identification
technology and MALDI=matrix assisted laser desorption/ionisation
mass spectrometry) in combination with in silico analysis
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fed into a Support Vector Machine (SVM) in a second
analysis step. The SVM was trained on a set of bona fide
examples for both classes. On this training set, the SVM
obtained the following results on three training sets
(signal—anchor—neither):
signal 96% sensitivity and 96% specificity
anchor 87% sensitivity and 98% specificity
neither 96% sensitivity and 97% specificity
These results are as good as the best claims in the
literature (note, however, that most tools only look at the
signal peptides and do not attempt to predict membrane
anchors).
For the default setting of this web interface, a list is
produced that simply classifies each input sequence in
either of the three categories “Signal”, “Anchor”, or
“Normal” (the latter indicating that neither signal peptide































Fig. 4 Scheme of centrifugal prefractionation of rat INS-1 proteins.
Different centrifugal force leads to enrichment of cellular components
such as mitochondria, microsomal and cytosolic proteins. The
cytosolic fraction was subjected to further fractionation by heparin
chromatography followed by separation on a 10% homogenous
polyacrylamide gel and protein identification by LC-MS/MS













Isoelectric Point  Isoelectric Point
4.5       5.0        5.5        6.0        6.5       7.0 4.5        5.0        5.5       6.0       6.5        7.0
P06303 (PPY) P06303 (PPY)
Fig. 5 2D-PAGE images of
differential protein expression
patterns in INS-1 cells incubated
under lipo/glucotoxic conditions
(10 mM glucose and 0.5 pal-
imate) versus control (5 mM
glucose). The selected spot of
protein (P06303) was identified
by MALDI-TOF as pancreatic
polypeptide Y [43]
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For the “verbose” mode, there is a much more detailed
table that has, for every input sequence, the following
columns:
seqID, Classification—these are the same as in the
default output discussed above.
Confidence—this qualifier can take the values
“Unique”, “Ambiguous”, or “No Class”, depending
on the SVM results. The SVM determines how well
the sequence scores fit its model of either of the three
classes. In the “Unique” case, the scores match only
one of the three classes, to which the sequence is then
assigned. In the “Ambiguous” case, the sequence
scores match more than one class—the sequence is
assigned to that class into which it fits best. In the “No
class” case, the scores do not match the expectations
for any of the three classes—the sequence is assigned
to that class for which the discrepancy is smallest.
D (Anchor), D (Normal), D (Signal)—these numbers
specify the “distances” to a line separating the three
classes (to use an intuitive metaphor). For a “Unique”
classification, only one of these “distances” is positive
(indicating that the sequence is “on the right side of
the fence”), whereas the other two are negative (“on
the wrong side of the fence” for the two other classes).
The larger the numbers, the clearer the classification.
For an “Ambiguous” classification, more than one of
the D’s is positive, for a “No class” classification, all
three D’s are negative.
SW-classification, SW-note—finally, sequences from
the SwissProt database already come with an annotation
regarding signal peptides and membrane anchors. For
them, we show the SwissProt classifications and any
additional comments on them for reference and com-
parison. Sequences from the HUMANGP, MOUSEGP,
and RATGP databases have “none” for both fields.
The HUMANGP, MOUSEGP, and RATGP databases
have been completely annotated with this prediction
algorithm, the results are displayed in the XR SIGNAL/
ANCHOR annotation lines and listed in Table 1.
Visualization and identification of putative secreted
proteins by MudPIT analysis enriched by heparin
chromatography
Heparin binding fractions of cell culture supernatants were
analyzed by LC-MS and MALDI-MS and the identification
of the putative markers were reported [43]. Five secreted
proteins were further confirmed: Chromogranin b, Pancre-
atic Polypeptide (PPY), Phospholipase A2, Fibronectin and
Vinculin were clearly shown to be secreted by INS-1. The
amount of secretion into the medium correlated strongly to
the insulin content of the INS-1 β-cells. Based on the organ
specify, PPY seemed to be one of the most interesting
candidates and was selected for further validation by
ELISA. PPY is a secretory glycoprotein with a widespread
distribution mostly expressed in endocrine pancreas. These
data were underlined by additional OGTT studies which
corroborate the findings and show clearly, that PPY is
secreted indepented from the glucose level in blood (see
Fig. 8). Furthermore it has been suggested that PPY has an
autocrine inhibitory effect on iAPP and insulin secretion by
different intra- and extracellular mechanism [45]. Ten
proteins were selected for further OGTT evaluation. Evalu-
ation/validation by immunoassays in a well-characterized
patient population was performed only with PPY. Pancreatic
Polypeptide levels are higher in diabetics than controls. A
more profound analysis has to demonstrate that the levels
correlate with β-cell failure and not other diabetes-related
phenomena (see Fig. 7). A priority application was made for
all candidates before a full validation was done.
Detection of PPY in human plasma—Proof-of-Concept
Clinical utility of the novel marker PPY was assessed by
measuring its levels in 10 diabetic patients depending on
injections of exogenous insulin and comparing the levels
with those measured in 10 patients with demonstrated
normal β-cell function [43].
The OGTT has fallen into disfavor as a tool to examine
the mechanism responsible for impaired glucose metabo-
lism in T2D subjects. The rate of glucose absorption varies
considerable from one subject to another and cannot be
quantified easily. Consequently, the rise in plasma glucose
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Fig. 6 1DE gel analysis of fractions eluted from heparin chromatog-
raphy. Fraction enriched with cytosolic rat INS-1 proteins was
prepared as stated in [43]. Gels were stained with colloidal Coomassie
blue and protein bands were identified by MudPIT [43]
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Table 1 List of identified secreted INS-1 proteins enriched by heparin chromatography [43]
Fraction SW.-Nr. Access. Nr. Status Full Protein Name kDa
Sup. S106_RAT P05964 Sec. Calcyclin (Prolactin receptor associated protein). 10.1
Hep. KV5C_MOUSE P01635 Sec. Ig kappa chain V-V region K2 precursor (Fragment). 12.6
Sup. TL19_MOUSE Q9CQU0 Sec. Thioredoxin-like protein p19 precursor 19.0
Sup. CYPC_MOUSE P30412 Sec. Peptidyl-prolyl cis-trans isomerase C (EC 5.2.1.8) 22.8
Hep. CYPB_RAT P24368 Sec. Peptidyl-prolyl cis-trans isomerase B prec. (EC 5.2.1.8) 23.0
Hep. TIM2_RAT P30121 Sec. Metalloproteinase inhibitor 2 precursor (TIMP-2) 24.3
Hep.; Sup. TRY1_RAT P00762 Sec. Trypsin I, anionic precursor (EC 3.4.21.4) 25.9
Hep.; Sup. TRY2_MOUSE P07146 Sec. Trypsin II, anionic precursor (EC 3.4.21.4) 26.2
Hep. PAHO_RAT P06303 Sec. Pancreatic prohormone prec. (Pancreatic polypeptide) 27.1
Hep.; Sup. IBP4_RAT P21744 Sec. Insulin-like growth factor binding protein 4 (IGFBP-4) 27.7
Hep. ER29_RAT P52555; P80749 Sec. Endoplasmic reticulum protein ERp29 prec. (ERp31). 28.6
Sup. PDX4_MOUSE O08807; Sec. Peroxiredoxin 4 (EC 1.11.1.-) (Prx-IV) 31.0
Hep.; Sup. SPRC_RAT P16975; O08953 Sec. SPARC precursor 34.4
Hep. FSL1_RAT Q62632 Sec. Follistatin-related protein 1 prec. (Follistatin-like 1). 34.6
Hep.; Sup. OSTP_RAT P08721 Sec. Osteopontin precursor (Secreted phosphoprotein 1) 34.9
Hep.; Sup. DRNG_MOUSE O55070 Sec. Deoxyribonuclease gamma precursor (EC 3.1.21.-) 35.7
Sup. CALU_RAT O35783 Sec. Calumenin precursor (Crocalbin) 37.0
Sup. CATM_MOUSE Q9JL96; Q91Z75 Sec. Cathepsin M precursor (EC 3.4.22.-). 37.4
Sup. CATB_RAT P00787; Sec. Cathepsin B precursor (EC 3.4.22.1) (Cathepsin B1) 37.4
Hep. CATL_RAT P07154 Sec. Cathepsin L prec. (EC 3.4.22.15) 37.6
Hep. IF35_MOUSE Q9DCH4 Sec. Eukaryotic translation initiation factor 3 subunit 5 38.0
Sup. RCN1_MOUSE Q05186 Sec. Reticulocalbin 1 precursor. 38.1
Sup. DKK3_MOUSE Q9QUN9 Sec. Dickkopf related protein-3 precursor (Dkk-3) 38.4
Hep. PGS2_RAT Q01129 Sec. Decorin precursor (Bone proteoglycan II) 39.8
Sup. CB45_RAT Q91ZS3 Sec. 45 kDa calcium-binding protein precursor (Cab45) 42.0
Hep. SELP_RAT P25236 Sec. Selenoprotein P precursor (SeP). 42.6
Hep. PAI1_RAT P20961 Sec. Plasminogen activator inhibitor-1 precursor (PAI-1) 45.0
Sup. T11B_RAT O08727 Sec. Tumor necrosis factor recept. superfamily member11B 46.2
Hep.; Sup. PEDF_MOUSE P97298 Sec. Pigment epithelium-derived factor precursor (PEDF) 46.2
Hep. HS47_RAT P29457 Sec. 47 kDa heat shock protein prec. 46.5
Sup. MFGM_RAT P70490 Sec. Lactadherin precursor (Milk fat globule-EGF factor 8) 47.4
Hep.; Sup. CRTC_RAT P18418; P10452 Sec. Calreticulin precursor (CRP55) (Calregulin) (HACBP) 48.0
Hep. LGMN_RAT Q9R0J8 Sec. Legumain precursor (EC 3.4.22.34) 49.4
Sup. NCB2_RAT Q9JI85 Sec. Nucleobindin 2 precursor (DNA-binding protein NEFA). 50.1
Hep. PCO1_RAT O08628 Sec. Procollagen C-proteinase enhancer protein precursor 50.2
Sup. VAS1_RAT O54715 Sec. Vacuolar ATP synthase subunit S1 prec. (EC 3.6.3.14) 51.1
Hep. HRA1_MOUSE Q9R118 Sec. Serine protease HTRA1 precursor (EC 3.4.21.-). 51.2
Hep. CLUS_RAT P05371 Sec. Clusterin precursor (Sulfated glycoprotein 2) (SGP-2) 51.3
Hep.; Sup. SRPX_RAT Q63769 Sec. Sushi repeat-containing protein SRPX prec. 51.5
Hep. ANT3_MOUSE P32261 Sec. Antithrombin-III precursor (ATIII). 52.0
Hep. LIPL_RAT Q06000 Sec. Lipoprotein lipase precursor (EC 3.1.1.34) (LPL). 53.0
Hep. SG3_MOUSE P47867 Sec. Secretogranin III precursor (SgIII). 53.3
Hep. NCB1_RAT Q63083; P97623 Sec. Nucleobindin 1 precursor (CALNUC) 53.5
Hep. ARSA_MOUSE P50428 Sec. Arylsulfatase A precursor (EC 3.1.6.8) (ASA) 53.7
Hep.; Sup. PRTP_MOUSE P16675 Sec. Lysosomal protective protein precursor (EC 3.4.16.5) 53.8
Hep.; Sup. PLTP_MOUSE P55065; Q99L70 Sec. Phospholipid transfer protein precursor 54.4
Sup. DPP2_RAT Q9EPB1 Sec. Dipeptidyl-peptidase II precursor (EC 3.4.14.2) 55.1
Hep. CPS1_MOUSE P03940 Sec. Cytochrome P450 XXIA1 (EC 1.14.99.10) 55.3
Sup. PDA3_RAT P11598 Sec. Protein disulfide isomerase A3 precursor (EC 5.3.4.1) 56.6
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Table 1 (continued)
Fraction SW.-Nr. Access. Nr. Status Full Protein Name kDa
Sup. PDI_RAT P04785; P13700 Sec. Protein disulfide isomerase precursor (PDI) 56.9
Hep. MM19_MOUSE Q9JHI0 Sec. Matrix metalloproteinase-19 precursor (EC 3.4.24.-) 59.1
Hep.; Sup. HEXA_MOUSE P29416; Q64246 Sec. Beta-hexosaminidase alpha chain prec. (EC 3.2.1.52) 60.6
Sup. TPP1_RAT Q9EQV6 Sec. Tripeptidyl-peptidase I precursor (EC 3.4.14.9) (TPP-I) 61.3
Hep. GPC1_RAT P35053 Sec. Glypican-1 precursor (HSPG M12). 61.7
Sup. ALBU_RAT P02770; P11382 Sec. Serum albumin precursor 68.7
Sup. ASM_MOUSE Q04519 Sec. Sphingomyelin phosphodiesterase prec. (EC 3.1.4.12) 69.9
Hep. SPL1_RAT P24054 Sec. SPARC-like protein 1 prec. (Matrix glycoprotein Sc1). 70.6
Hep.; Sup. KNG_RAT P08934; P08933 Sec. Kininogen precursor 70.9
Sup. IDUA_MOUSE P48441 Sec. Alpha-L-iduronidase precursor (EC 3.2.1.76). 71.1
Hep. GR78_RAT P06761 Sec. 78 kDa glucose-regulated protein precursor (GRP 78) 72.3
Hep. PDA4_RAT P38659 Sec. Protein disulfide isomerase A4 precursor (EC 5.3.4.1) 72.8
Hep.; Sup. BGLR_MOUSE P12265; Q61601 Sec. Beta-glucuronidase precursor (EC 3.2.1.31). 74.2
Hep. FBL1_MOUSE Q08879; Q08878 Sec. Fibulin-1 prec. (Basement-membrane protein 90) 78.0
Hep. SM3B_MOUSE Q62177 Sec. Semaphorin 3B precursor (Semaphorin A) 82.8
Sup. PLO1_RAT Q63321 Sec. Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 83.6
Hep. LOL3_MOUSE Q9Z175; Q9JJ39 Sec. Lysyl oxidase homolog 3 precursor (EC 1.4.3.-) 83.6
Hep.; Sup. AD10_MOUSE O35598 Sec. ADAM 10 precursor (EC 3.4.24.-) 83.9
Sup. MEPA_MOUSE P28825 Sec. Meprin A alpha-subunit precursor (EC 3.4.24.18) 84.1
Hep. PLO3_MOUSE Q9R0E1 Sec. Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 84.9
Hep.; Sup. A4_RAT P08592 Sec. Alzheimer's disease amyloid A4 protein homolog 86.6
Sup. APP2_RAT P15943 Sec. Amyloid-like protein 2 precursor 86.8
Hep. ENPL_MOUSE P08113; P11427 Sec. Endoplasmin prec. (Endoplasmic reticulum protein 99) 92.4
Sup. DAG1_MOUSE Q62165; Q61094 Sec. Dystroglycan precursor 96.8
Hep. FPRP_RAT Q62786 Sec. Prostaglandin F2 receptor negative regulator precursor 98.7
Hep. NAH5_RAT Q9Z0X2 Sec. Sodium/hydrogen exchanger 5 Na(+)/H(+) exchanger 99.0
Hep.; Sup. DSC3_MOUSE P55850; O55110 Sec. Desmocollin 3 precursor. 100.6
Hep. TSP3_MOUSE Q05895 Sec. Thrombospondin 3 precursor. 103.9
Hep.; Sup. PEX6_RAT P54777; O55097 Sec. Peroxisome assembly factor-2 (PAF-2) 104.4
Hep. ITH2_MOUSE Q61703 Sec. Inter-alpha-trypsin inhibitor heavy chain H2 precursor 105.9
Hep. CA16_MOUSE Q04857 Sec. Collagen alpha 1(VI) chain precursor. 108.4
Hep. AMD_RAT P14925; P70710 Sec. Peptidyl-glycine alpha-amidating monooxygenase 108.6
Sup. CLS1_MOUSE Q9EPL2 Sec. Calsyntenin-1 precursor. 108.8
Sup. OXRP_RAT Q63617 Sec. 150 kDa oxygen-regulated protein precursor (Orp150) 111.2
Hep. M2B1_MOUSE O09159; O55037 Sec. Lysosomal alpha-mannosidase precursor EC 3.2.1.2 114.5
Sup. M2B2_MOUSE O54782 Sec. Epididymis-specific alpha-mannosidase (EC 3.2.1.24) 115.6
Hep.; Sup. TSP1_MOUSE P35441 Sec. Thrombospondin 1 precursor. 129.6
Hep.; Sup. LMG2_MOUSE Q61092 Sec. Laminin gamma-2 chain precursor 130.1
Hep. DIA1_MOUSE O08808 Sec. Diaphanous protein homolog 1 139.3
Sup. RGSC_RAT O08774; O88383 Sec. Regulator of G-protein signaling 12 (RGS12). 150.4
Hep.; Sup. A2MG_RAT P06238 Sec. Alpha-2-macroglobulin precursor (Alpha-2-M). 163.6
Sup. A1I3_RAT P14046 Sec. Alpha-1-inhibitor III precursor. 163.7
Hep.; Sup. LMG3_MOUSE Q9R0B6 Sec. Laminin gamma-3 chain precursor 172.2
Hep. LMG1_MOUSE P02468 Sec. Laminin gamma-1 chain precursor (Laminin B2 chain). 177.2
Sup. CO3_RAT P01026 Sec. Complement C3 precursor 186.3
Sup. LTB1_RAT Q00918 Sec. Latent transforming growth factor beta binding prot. 1 186.5
Hep. LMB1_MOUSE P02469 Sec. Laminin beta-1 chain precursor (Laminin B1 chain). 196.8
Hep. LMA4_MOUSE P97927; O88785 Sec. Laminin alpha-4 chain precursor. 201.7
Hep. PGG2_RAT Q00657 Sec. Chondroitin sulfate proteoglycan NG2 precursor 251.8
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concentration differed markedly from one subject to
another and is constantly changing. This presents an ever-
fluctuating glycemic stimulus that, when combined with
intrinsic differences in β-cell function from one individual
to another, leads to large variations in the plasma insulin
profile between subjects as shown in [45]. Because the two
primary variables of interest—plasma glucose and plasma
insulin concentration—are changing simultaneously, it is
difficult to draw any conclusion about insulin secretion or
insulin sensitivity. Lastly, it is difficult to quantitate changes
in hepatic glucose production after glucose ingestion
because the rate of entry of glucose into circulation is
unknown. In order to investigate the influence of the
plasma glucose concentration on the PPY level, an OGTT
with four healthy subjects were performed and all have
revealed very similar results. Our investigations indicate
that early insulin secretion, absolute insulin concentration at
30 min, the incremental insulin concentration (ΔI) at
30 min, or the incremental insulin concentration factored
by the incremental glucose concentration (ΔI/ΔG) at 30 min
had less predictive value for the β-cell function than the
determination of PPY. PPY absolute concentration did not
vary so much between the healthy individuals and it was
shown that the secretion rate to be independent of the
plasma glucose and insulin concentration. Furthermore, the
PPY plasma concentration between the healthy individuals
was very constant and only significantly elevated in T2D
and IGT+IFG individuals as shown in Fig. 7 and proved to
be a better predictor of progression to T2D than OGTT.
Since the plasma glucose concentration is the primary
determinant of insulin secretion, it is obvious that fasting
insulin and glucose concentration alone can not be used to
predict the progression of normal-glucose-tolerant subjects
to T2D. It is anticipated that our results and methods are
able to establish a framework for the identification of
additional marker candidates that need to be examined and
provide a sound scientific basis for the identification and more
precise definition of predictive biomarkers in T2D.
Summary
Individuals with T2D are characterized by abnormalities in
insulin action and insulin secretion. However, despite
intensive investigation, the proteins/peptides or genes
responsible for the insulin resistance and impaired insulin
secretion remain undefined. The candidate-proteins/genes
approach has failed to identify any specific proteins or
genes or combination of proteins/genes that can account for
even a minority of adult cases of T2D. Although a number
of laboratories have initiated genome- and proteome-wide
Table 1 (continued)
Fraction SW.-Nr. Access. Nr. Status Full Protein Name kDa
Sup. FINC_RAT P04937 Sec. Fibronectin precursor (FN). 272.3
Hep. PGBM_MOUSE Q05793 Sec. Basement memb.-spec. heparan sulfate proteoglycan 398.0
Hep.; Sup. LMA5_MOUSE Q61001 Sec. Laminin alpha-5 chain precursor. 403.7
Hep.; Sup. LRP2_RAT P98158 Sec. Low-density lipoprotein receptor-related protein 2 518.9





















Fig. 7 Primary results: Validation of PPY in human blood / plasma
samples in five different healthy donors by ELISA [43]




































Fig. 8 Means of plasma glucose, insulin and PPY concentration
during a 100 g OGTT in 4 healthy normal weight individuals. The
results indicate that early insulin secretion has a less predictive value
for the β-cell function than the determination of PPY levels. The
absolute PPY concentration varies much less between healthy
individuals and the results show that the secretion rate of PPY from
the endocrine pancreas is independent of the plasma glucose and
insulin concentration [43]
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search to identify potential susceptibility targets for T2D,
consistent and reproducible linkage to predictive markers
has yet to merge. It has been suggested that a more precise
definition of the diabetic phenotype may prove useful in
delineating diabetogenetic genes or gene products. This
review should provide an inside into new analytical strategy
for the specific enrichment and identification of secreted and
pancreas specific proteins/peptides, which are responsible
for abnormalities of insulin secretion in T2D and which may
serve as predictive markers for β-cell function.
All together the analysis in [43] resulted in the identifica-
tion of 391 different gene products derived from the INS
cells. One hundred eighty-eight proteins bound to the heparin
matrix, 101 of which were identified as secreted proteins
with signaling functions and are listed in Table 1. Forty-four
of the enriched proteins had not been detected by 2-DE
without previous enrichment by combination of subcellular
prefractionation and heparin chromatography. Heparin chro-
matography specifically enriched several enzymes that had not
been identified before [46–49], like peptidyl-glycine alpha-
amidating monooxygenase, sodium/hydrogen exchanger 5,
etc. The identified proteins can be divided into five classes:
& Hormones and related molecules (amylin, pancreatic
polypeptide, neuroendocrine convertase)
& Protease inhibitors (e.g. cystatin)
& Secretory vesicle proteins (e.g. chromogranin,
secretogranin)
& Cell adhesion or extracellular matrix proteins (e.g.
protocadherin)
& Secreted enzymes (e.g. phospholipase)
From all identified secreted proteins only pancreatic
polypeptide Y (PPY) was identified as pancreas specific,
fulfilling the criteria of a predictive marker and hence was
selected for further validation [43].
PPY (pancreatic polypeptide Y), a 78-amino acid peptide
is synthesized in pancreatic islets of Langerhans and acts as a
regulator of pancreatic and gastrointestinal functions. The
peptide is structurally similar to another pancreatic hormone
family consisting of neuropeptide Y (NPY) b, and peptide
YY (PYY) which are closely related to each other. The
propeptide is enzymatically cleaved to yield the mature active
peptide with amidated C-terminal ends while receptor binding
and activation functions reside in the N- and C-termini
respectively. PPY occurs in neurons, intestinal endocrine
cells, and the pancreas and exists as monomer and dimer. The
physiological role for the icosapeptide has not yet been
elucidated. PPY was identified as specifically secreted by the
endocrine pancreas and it is mainly produced by β-and f-cells
[47]. Its plasma concentration has been used as a marker of
parasympathetic activity. Recent work in rodents suggests
that there is both sympathetic and parasympathetic innerva-
tion of white adipose tissue and that parasympathetic activity
is anabolic resulting in lipid accumulation [48]. It was
examined whether in humans increased PP levels are
associated with increased β-cell dysfunctions, and thereby
early β-cell failure in T2D. Together with amylin, the
peptide has been shown to be the precursor for the amyloid
deposits frequently observed in patients with T2D [50–53].
At very high doses PPY inhibits insulin secretion by the
perfused rat pancreas in vitro [54] and pancreatic PPY
and amylin deposits have been shown to precede the
appearance of glucose intolerance in spontaneously dia-
betic monkeys [55]. In the course of the study published in
[43], the authors were able to demonstrate that elevated
plasma PPY levels can be observed in IGT and IFG subjects,
in glucose-intolerance first degree relatives of type 2 diabetic
patients (see Fig. 7), and in animal models of diabetes.
Although pancreatic and plasma PPY levels were signifi-
cantly elevated, hyperglycemia and hyperinsulinemia were
not observed (see Fig. 8). In summary, based on the findings/
observation, the evidence that PPY is responsible for some
of the defects in pancreatic islets is very strong and it seems
that PPY plays an important role in impaired β-cell function
in T2D.
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